<DOC>
	<DOCNO>NCT02615080</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled , parallel group , Phase 2 trial evaluate CRD007 administer orally b.i.d 14 week treatment asthma . CRD007 give add background commonly use controller medication , i.e . inhale corticosteroid ( ICS ) without long-acting beta2-agonist ( LABA ) . By gradually reduce background controller medication , efficacy safety CRD007 evaluate top several dose level medication .</brief_summary>
	<brief_title>Safety Efficacy CRD007 Adult Asthma Subjects</brief_title>
	<detailed_description>The present trial include subject diagnose asthma . The trial involve total 11 visit ( Visit 1-2 screen visit , visit 3 randomisation visit , visit 4-10 treatment visit visit 11 follow-up visit ) . The subject monitor medically qualified staff every second week clinic visit , reduction background controller medication reduce , asthma control . Between visit clinic subject complete diary .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pemirolast</mesh_term>
	<criteria>Written inform consent Age ≥18 year old Diagnosis asthma accord Global Initiative Asthma ( GINA ) Guidelines Atopic phenotype assess investigator Treated ICS LABA least 12 week prior Visit 1with protocol define daily dos Blood eosinophil ≥0.15*109/L Visit 1 Demonstration force expiratory volume one second ( FEV1 ) &gt; 60 % predict value Visit 1 Demonstration ACQ6 ≥ 0.5 ≤1.5 Visit 1 Reversibility least 12 % 200 mL FEV1 Lower respiratory tract infection &lt; 6 week prior Visit 1 Current smoker Significant concurrent , uncontrolled medical condition define protocol Others , define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>